Kiniksa Pharmaceuticals International Plc (KNSA)
77.09
-0.82
(-1.05%)
USD |
NASDAQ |
Sep 08, 16:00
80.00
+2.91
(+3.77%)
After-Hours: 20:00
Kiniksa Pharmaceuticals International Enterprise Value : 5.494B for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 5.494B |
| September 04, 2026 | 5.558B |
| September 03, 2026 | 5.758B |
| September 02, 2026 | 5.713B |
| September 01, 2026 | 5.665B |
| August 31, 2026 | 5.615B |
| August 28, 2026 | 5.572B |
| August 27, 2026 | 5.706B |
| August 26, 2026 | 5.618B |
| August 25, 2026 | 5.737B |
| August 24, 2026 | 5.673B |
| August 21, 2026 | 5.646B |
| August 20, 2026 | 5.602B |
| August 19, 2026 | 5.784B |
| August 18, 2026 | 5.682B |
| August 17, 2026 | 5.657B |
| August 14, 2026 | 5.468B |
| August 13, 2026 | 5.552B |
| August 12, 2026 | 5.577B |
| August 11, 2026 | 5.550B |
| August 10, 2026 | 5.451B |
| August 07, 2026 | 5.414B |
| August 06, 2026 | 5.449B |
| August 05, 2026 | 5.572B |
| August 04, 2026 | 5.409B |
| Date | Value |
|---|---|
| August 03, 2026 | 5.207B |
| July 31, 2026 | 5.280B |
| July 30, 2026 | 5.581B |
| July 29, 2026 | 5.793B |
| July 28, 2026 | 5.678B |
| July 27, 2026 | 4.437B |
| July 24, 2026 | 4.383B |
| July 23, 2026 | 4.400B |
| July 22, 2026 | 4.352B |
| July 21, 2026 | 4.439B |
| July 20, 2026 | 4.363B |
| July 17, 2026 | 4.470B |
| July 16, 2026 | 4.248B |
| July 15, 2026 | 4.294B |
| July 14, 2026 | 4.316B |
| July 13, 2026 | 4.235B |
| July 10, 2026 | 4.430B |
| July 09, 2026 | 4.581B |
| July 08, 2026 | 4.533B |
| July 07, 2026 | 4.730B |
| July 06, 2026 | 4.378B |
| July 02, 2026 | 4.515B |
| July 01, 2026 | 4.387B |
| June 30, 2026 | 4.470B |
| June 29, 2026 | 4.327B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Autolus Therapeutics Plc | 726.29M |
| Barinthus Biotherapeutics Plc | -19.04M |
| Scancell Holdings Plc | -- |
| OptiBiotix Health Plc | -- |
| Immunocore Holdings Plc | 1.375B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 25.43M |
| Revenue (Quarterly) | 243.60M |
| Total Expenses (Quarterly) | 218.17M |
| EPS Diluted (Quarterly) | 0.305 |
| Gross Profit Margin (Quarterly) | 54.10% |
| Profit Margin (Quarterly) | 10.44% |
| Earnings Yield | 1.28% |
| Operating Earnings Yield | 1.59% |
| Normalized Earnings Yield | 1.276 |